Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathy
Maria Giuseppa Vitale(University of Modena and Reggio Emilia), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Giovanna Vitale(University of Campania "Luigi Vanvitelli"), Carmela Barbato(Ospedale Antonio Cardarelli), Anna Crispo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Habetswallner(Ospedale Antonio Cardarelli), Angela Serena Maione(Centro Cardiologico Monzino), Bernardo Maria De Martino(Ospedale Antonio Cardarelli), Sandra Eisenwagen, Riccardo Ronga(Ospedale Antonio Cardarelli), Dario Arundine(Ospedale Antonio Cardarelli), Assunta Luongo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 2
Related Papers
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
|European Urology|2021|110
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108